Glatiramer acetate for multiple sclerosis: A comprehensive review of mechanisms and clinical efficacy

Expert Review of Neurotherapeutics

Volumn 2, Issue 3, 2002, Pages 285-294

  Zvartau Hind, Marina ^a   Caon, Christina ^a   Zabad, Rana ^a   Tselis, Alexandros ^a   Lisak, Robert ^a   Khan, Omar ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

Clinical trials; Copaxone; Copolymer 1; Glatiramer acetate; Multiple sclerosis; Relapsing remitting

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEUROSCIENCE; REVIEW; SKIN NECROSIS;

EID: 0036283486     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.3.285     Document Type: Review

References (73)

1. Hirshfeld T et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
2. Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis
3. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis
4. The effect of Cop-1, a synthetic polypeptide, on chronic relapsing experimental experimental allergic encephalomyelitis in guinea-pigs
5. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea-pigs and rabbits with bovine and human basic encephalitogen
6. Effect of treatment with copolymer 1(Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)
7. Direct binding of myelin basic protein and synthetic polymer co-polymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity
8. Binding of random co-polymers of three amino acids to class II MHC molecules
9. Mechanisms of action of glatiramer acetate in multiple sclerosis
10. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS
11. Mechanisms of immunomodulation by glatiramer acetate
12. Human and murine CD4 T-cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate
13. Long-term therapy with glatiramer acetate in multiple sclerosis: Effect on T-cells
14. Characterization of T-cell lines derived from glatiramer-acetate-treated multiple sclerosis patients
15. Lymphocyte migration and multiple sclerosis: Relation with disease and therapy
16. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by co-polymer 1
17. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop-1
18. Synthetic co-polymer 1 inhibits human T-cell lines specific for myelin basic protein
19. Co-polymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T-cell receptor antagonism in addition to major histocompatibility complex blocking
20. The expanding universe of T-cell subsets: Th 1, Th2 and more
21. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone
22. Immunogenic potentials of copolymer 1 in normal human lymphocytes
23. Co-polymer I: Effect on normal human lymphocytes
24. Human cellular immune response to co-polymer I and myelin basic protein
25. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells
26. Multiple sclerosis: Comparison of copolymer-1-reactive T-cell lines from treated and untreated subjects reveals cytokine shift from T-helper 1 to T-helper 2 cells
27. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation
28. Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy
29. Glatiramer acetate specific T-cell lines produce brain derived neurotrophic factor after activation upon antigen challenge in vitro: A novel mechanism of action?
30. Autoimmune T-cells protect neurons from secondary degeneration after central nervous system axotomy
31. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis
32. T-cell immunity to co-polymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies
33. Activated human T-cells, B-cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation?
34. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report
35. Multiple sclerosis: A trial of synthetic polypetide
36. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
37. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
38. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
39. Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a Phase III multicenter, double-blind, placebo-controlled trial
40. Assessment of the efficacy of co-polymer-1 in the treatment of relapsing-remitting multiple sclerosis by quantitative MRI
41. Extended use of glatiramer acetate (Copaxone) is well-tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
42. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
43. Results of the long-term (8 year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis
44. Glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
45. A comparison of observational studies and randomized, controlled trials
46. Randomized controlled trials, observational studies and the hierarchy of research designs
47. The role of MRI as surrogate outrcome measure in multiple sclerosis
48. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
49. The effect of interferon beta on blood-brain barrier disruptions demonstrated by contrast enhanced MRI in relapsing-remitting multiple sclerosis
50. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'
51. Correlating MRI and clinical disease activity in multiple sclerosis: Relevance of hypointense lesions on short TR/short TE (T1-weighted) spin-echo images
52. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy
53. A longitudinally MRI study of histopathologically defined hypointense multiple sclerosis lesions
54. Accumulation of hypointense lesions (black holes) on T1-spin-echo MRI correlates with disease progression in multiple sclerosis
55. Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications
56. Use of brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting multiple sclerosis
57. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive multiple sclerosis
58. A prospective open-label treatment trial to compare the effect of IFN-beta-1a (Avonex), IFN-beta-1b (Betaseron) and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
59. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron) and glatiramer acetate (Copaxone) on the Relapse rate in relapsing-remitting multiple sclerosis: Results after 18 months of therapy
60. Comparison of new immunomodulatory treatments in the early stages of MS
61. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of co-polymer 1
62. Oral and sc. administration of glatiramer acetate (COP 1) have similar effects in chronic relapsing EAE
63. Effect of glatiramer acetate (Copaxone) given orally in human patients: Interleukin-10 production during a Phase 1 trial
64. Clinical features
65. Prognostic factors in Multiple Sclerosis
66. Primary Progressive MS: Clinical and MRI characteristics at entry into the PROMiSe trial
67. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein
68. Combination therapy with glatiramer acetate (copolymer-1) and a Type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis
69. A trial to assess the safety of combining therapy with interferon beta-1A and glatiramer acetate in patients with relapsing MS
70. Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate
71. Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure
72. Promoting axonal regeneration in the central nervous system by enhancing the cell body response to axotomy